1. CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives
- Author
-
Steve A. Ward, Ian C Boulton, Solomon Nwaka, Kelly Chibale, Christian Doerig, Michael Lanzer, Donatella Taramelli, Ian Bathurst, Henri Vial, BMC, Ed., TropMedPharma Consulting Ltd, Special programme for research & training in tropical diseases, Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Medicines for Malaria Venture (MMV), Université de Genève = University of Geneva (UNIGE), Department of Parasitology, Universität Heidelberg [Heidelberg], Department of sanità pubblica-microbiologia-virologia, Università degli Studi di Milano = University of Milan (UNIMI), Dynamique des interactions membranaires normales et pathologiques (DIMNP), Université Montpellier 1 (UM1)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Inserm-EPFL Joint Laboratory, Ecole Polytechnique Fédérale de Lausanne (EPFL)-Global Health Institute, Department of Chemistry, University of Cape Town, Liverpool School of Tropical Medicine (LSTM), Faculty of Science, Université de Genève (UNIGE), Università degli Studi di Milano [Milano] (UNIMI), and Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Université Montpellier 2 - Sciences et Techniques (UM2)-Université Montpellier 1 (UM1)
- Subjects
Plasmodium ,Resistance ,Drug Resistance ,Public administration ,wa_20_5 ,0302 clinical medicine ,[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,Drug Discovery ,qv_256 ,media_common ,0303 health sciences ,Drug discovery ,Health Policy ,Stakeholder ,Medical research ,Anti-malarial Drug ,3. Good health ,Infectious Diseases ,MESH: Health Priorities ,MESH: Research ,Drug development ,Bed Net Distribution ,[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases ,MESH: Drug Resistance ,Mass Drug Administration ,MESH: Health Policy ,Malaria Elimination ,Plasmodium-Falciparum ,lcsh:Arctic medicine. Tropical medicine ,Anti malarial ,Mass Drug Administration Campaign ,lcsh:RC955-962 ,Drug Resistant Tuberculosis ,Global Malaria Community ,030231 tropical medicine ,MESH: Malaria ,Biology ,lcsh:Infectious and parasitic diseases ,Vivax Malaria ,Antimalarials ,03 medical and health sciences ,MESH: Drug Discovery ,MESH: European Union ,Humans ,media_common.cataloged_instance ,lcsh:RC109-216 ,European Union ,European union ,Health policy ,030304 developmental biology ,Window of opportunity ,MESH: Humans ,Health Priorities ,business.industry ,MESH: Plasmodium ,Research ,MESH: Antimalarials ,Malaria ,Biotechnology ,Commentary ,Parasi ,Parasitology ,business - Abstract
Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted. The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade.
- Published
- 2010